Aardvark Therapeutics (AARD) Other Accumulated Expenses (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Other Accumulated Expenses data on file, last reported at $755000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 18.9% year-over-year to $755000.0; the trailing twelve-month figure through Mar 2026 stood at $755000.0 (up 18.9% YoY), and the FY2025 full-year result was $422000.0, up 143.93% from the prior year.
• Other Accumulated Expenses advanced to $755000.0 in Q1 2026, from $422000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $755000.0 in Q1 2026 to a low of $173000.0 in Q4 2024.
• A 3-year average of $435333.3 and a median of $371000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 143.93% in 2025 and grew 18.9% in 2026, its largest moves.
• Tracing AARD's Other Accumulated Expenses over 3 years: stood at $173000.0 in 2024, then jumped by 143.93% to $422000.0 in 2025, then soared by 78.91% to $755000.0 in 2026.
• Business Quant data shows AARD's Other Accumulated Expenses at $755000.0 in Q1 2026, $422000.0 in Q4 2025, and $320000.0 in Q3 2025.